Business Description
Pasithea Therapeutics Corp
NAICS : 541714
SIC : 2834
ISIN : US70261F2020
Description
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 283.67 | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.49 | |||||
| 9-Day RSI | 36.37 | |||||
| 14-Day RSI | 38.85 | |||||
| 3-1 Month Momentum % | -33.33 | |||||
| 6-1 Month Momentum % | -55.81 | |||||
| 12-1 Month Momentum % | -63.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.82 | |||||
| Quick Ratio | 14.82 | |||||
| Cash Ratio | 14.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 15.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -74.66 | |||||
| ROA % | -68.3 | |||||
| ROIC % | -172.82 | |||||
| ROC (Joel Greenblatt) % | -6885.67 | |||||
| ROCE % | -75.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.15 | |||||
| Price-to-Tangible-Book | 0.29 | |||||
| EV-to-EBIT | 0.55 | |||||
| EV-to-EBITDA | 0.57 | |||||
| EV-to-FCF | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 0.29 | |||||
| Price-to-Net-Cash | 0.3 | |||||
| Earnings Yield (Greenblatt) % | 181.82 | |||||
| FCF Yield % | -451.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KTTA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pasithea Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -14.82 | ||
| Beta | 1 | ||
| 3-Year Sharpe Ratio | -0.94 | ||
| 3-Year Sortino Ratio | -1.13 | ||
| Volatility % | 53.65 | ||
| 14-Day RSI | 38.85 | ||
| 14-Day ATR ($) | 0.261875 | ||
| 20-Day SMA ($) | 2.736315 | ||
| 12-1 Month Momentum % | -63.65 | ||
| 52-Week Range ($) | 2.2 - 9.25 | ||
| Shares Outstanding (Mil) | 1.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pasithea Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pasithea Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pasithea Therapeutics Corp Frequently Asked Questions
What is Pasithea Therapeutics Corp(KTTA)'s stock price today?
The current price of KTTA is $2.48. The 52 week high of KTTA is $9.25 and 52 week low is $2.20.
When is next earnings date of Pasithea Therapeutics Corp(KTTA)?
The next earnings date of Pasithea Therapeutics Corp(KTTA) is 2025-05-14 Est..
Does Pasithea Therapeutics Corp(KTTA) pay dividends? If so, how much?
Pasithea Therapeutics Corp(KTTA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers